Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Can-Fite BioPharma Ltd.

< Previous 1 2 Next >
Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Present at the Emerging Growth Conference on July 13, 2023
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Reports 2022 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.